Targeting both

Inflammation and

Mitochondrial Dysfunction

for the treatment of Diseases

with high unmet need

Unlocking the Full Therapeutic Value of Natural Cell Protection Pathways

OMEICOS is focused on developing therapies that have the potential for a significant impact on cardiovascular, inflammatory and mitochondrial diseases with high unmet need. Our pipeline is based on our proprietary approach to target one of nature’s most important cell-protective pathways and industry-leading knowledge of omega-3 fatty acid metabolism and biology.

OMEICOS lead compound, OMT-28, has recently completed a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from atrial fibrillation. OMT-28 proved its excellent safety and tolerability profile, already shown in Phase I with 75 healthy volunteers.

In addition, the study demonstrated a significant positive effect on a number of inflammatory biomarkers, among them IL-6 and GDF-15, the strongest independent predictors of mortality and disease progression in cardiovascular disease.

The company is planning a robust clinical proof-of-concept study to confirm OMT-28’s broad anti-inflammatory effect and to leverage the validated link between reduction of CV inflammation and significant reduction of adverse events in patients with Coronary Artery Disease.

OMEICOS has also demonstrated the positive effect of OMT-28 in mitochondrial dysfunction and plans for a proof-of-concept clinical study in myopathy/cardiomyopathy in patients with mitochondriopathies.

In addition, OMT-28 has shown potential for the application to other disease areas such as ophthalmology.

Latest Press Release

September 3, 2019
OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer
Read more

Upcoming Events

June 13 -16, 2022
BIO International Convention 2022
Read more

Pipeline